The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lyadov V.K.

Clinical Oncology Hospital No. 1

Nersesova T.A.

City Clinical Oncology Hospital One of the Moscow Healthcare Department

Pokataev I.A.

City Clinical Oncology Hospital One of the Moscow Healthcare Department

Lyadova M.A.

City Clinical Oncology Hospital One of the Moscow Healthcare Department

Predictors for the development of immune-mediated adverse events during treatment with immune checkpoint inhibitors

Authors:

Lyadov V.K., Nersesova T.A., Pokataev I.A., Lyadova M.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2021;10(2): 55‑61

DOI: 10.17116/onkolog20211002155

Views: 1928

Downloaded: 79

Download PDF (RU)
Contact the author
Table of contents

PREDICTORS FOR THE DEVELOPMENT OF IMMUNE-MEDIATED ADVERSE EVENTS DURING TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS
PREDICTORS FOR THE DEVELOPMENT OF IMMUNE-MEDIATED ADVERSE EVENTS DURING TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS

To cite this article:

Lyadov VK, Nersesova TA, Pokataev IA, Lyadova MA. Predictors for the development of immune-mediated adverse events during treatment with immune checkpoint inhibitors. P.A. Herzen Journal of Oncology. 2021;10(2):55‑61. (In Russ.)
https://doi.org/10.17116/onkolog20211002155

 
Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Immune checkpoint inhi­bitors as a component of perioperative therapy in patients with rese­ctable esophageal and cardioesophageal junction cancer. P.A. Herzen Journal of Onco­logy. 2024;(5):62-68
Physical reha­bilitation in sarcopenia: modern approaches. (A lite­rature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(3):56-61
Impact of alco­hol consumption on nature of nutrition, meta­bolism and human target organs. Part 1. Meta­bolic dysfunction. Russian Journal of Preventive Medi­cine. 2024;(8):87-93
Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chro­nic kidney disease. Russian Journal of Preventive Medi­cine. 2024;(8):114-120
Clinical consequences of the sarcopenic obesity. Part 2. Cardiovascular diseases and osteoporosis. Russian Journal of Preventive Medi­cine. 2024;(9):60-66
Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):15-22
Modu­lation of oxidative stress as an early symptom of sarcopenia in type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(10):108-116
Impact of alco­hol consumption on nature of nutrition, meta­bolism and human target organs. Part 2. Basic principles of nutritional inte­rvention. Russian Journal of Preventive Medi­cine. 2024;(10):131-136
Local cyto­kine profile of the endo­metrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peri­pheral blood mono­nuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54
Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99

The use of immune check-point inhibitors has led to a paradigm shift in drug therapy in oncology. The use of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies could achieve a significant increase in objective response and overall survival rates in a number of malignant tumor localizations. Exerting an effect on the immune system, the drugs in this group often lead to the development of immune-mediated adverse toxic reactions, including severe and even fatal ones. The gastrointestinal tract, skin, endocrine glands, liver, and lung are most commonly affected, although any tissue can be a potential target for the development of these autoimmune processes. Searching for the predictors of undesirable adverse reactions is required for the early detection and successful relief of complications of therapy with immune checkpoint inhibitors, as well as for further personalization of therapy for patients with common types of cancer.

Keywords:

immunotherapy
immune-mediated adverse events
sarcopenia

Authors:

Lyadov V.K.

Clinical Oncology Hospital No. 1

Nersesova T.A.

City Clinical Oncology Hospital One of the Moscow Healthcare Department

Pokataev I.A.

City Clinical Oncology Hospital One of the Moscow Healthcare Department

Lyadova M.A.

City Clinical Oncology Hospital One of the Moscow Healthcare Department

Received:

14.10.2020

Accepted:

18.12.2020

List of references:

  1. Li B, Chan HL, Chen P. Immune checkpoint Inhibitors: Basics and challenges. Curr Med Chem. 2019;26(17):3009-3025. https://doi.org/10.2174/0929867324666170804143706
  2. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148.  https://doi.org/10.1016/j.ejca.2015.11.016
  3. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-574.  https://doi.org/10.1093/annonc/mdv623
  4. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290:84-89.  https://doi.org/10.1126/science.290.5489.84
  5. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001;1(3):220-228.  https://doi.org/10.1038/35105024
  6. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100(14):8372-8377. https://doi.org/10.1073/pnas.1533209100
  7. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyteassociated antigen 4. J Exp Med. 2000;192(2):303-310.  https://doi.org/10.1084/jem.192.2.303
  8. Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018;33(4):649-663.  https://doi.org/10.1016/j.ccell.2018.02.010
  9. Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P, Liu Y. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 2018;28(4):416-432.  https://doi.org/10.1038/s41422-018-0011-0
  10. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813-824.  https://doi.org/10.1093/intimm/dxm057
  11. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767-1778. https://doi.org/10.1056/nejmra1514296
  12. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543-9553. https://doi.org/10.1128/mcb.25.21.9543-9553.2005
  13. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313-326.  https://doi.org/10.1016/j.cell.2018.09.035
  14. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824-1835. https://doi.org/10.1056/NEJMoa1709030
  15. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.  https://doi.org/10.1056/NEJMc1509660
  16. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017. https://doi.org/10.1056/NEJMoa1414428
  17. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O’Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591-5598. https://doi.org/10.1158/1078-0432.ccr-09-1024
  18. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283-2289. https://doi.org/10.1200/jco.2005.04.5716
  19. Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, Abitbol V, Chaussade S, Coriat R. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12(3):301-308.  https://doi.org/10.1007/s11523-017-0495-4
  20. Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69(11):1751-1763. https://doi.org/10.1002/acr.23177
  21. Pedersen M, Andersen R, Nørgaard P, Jacobsen S, Thielsen P, Thor Straten P, Svane IM. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63(12):1341-1346. https://doi.org/10.1007/s00262-014-1607-y
  22. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2(1):35.  https://doi.org/10.1186/s40425-014-0035-z
  23. Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer. 2015;3:19.  https://doi.org/10.1186/s40425-015-0064-2
  24. Xiao X, Chang C. Diagnosis AND classification of drug-induced autoimmunity (DIA). J Autoimmun. 2014;48-49:66-72.  https://doi.org/10.1016/j.jaut.2014.01.005
  25. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81-88.  https://doi.org/10.1016/j.jhep.2013.02.022
  26. Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, Lawson D, Bartell H, Kudchadkar R, Gunter NT, Mehnert JM, Lipson EJ. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer. 2014;2(1):33.  https://doi.org/10.1186/s40425-014-0033-1
  27. Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, Zhao M, Zhang B, Jiang W, Lin Z, Ma Y, Yang Y, Huang Y, Zhao H, Xu R, Hong S, Zhang L. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer. 2019;7(1):322.  https://doi.org/10.1186/s40425-019-0808-5
  28. Lyadov VK, Bulanova EA, Seryakov AP. Sarcopenia as a leading component of malignant cachexia syndrome. Russian Journal of Gastroenterology, Hepatology, Coloproctology= Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2012;1:4-8. (In Russ.).
  29. Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, Gervais C, Jouinot A, Chapron J, Giraud F, Wislez M, Alexandre J, Blanchet B, Goldwasser F. The impact of body composition on severe toxicity of nivolumab. Eur J Cancer. 2020;124:170-177.  https://doi.org/10.106/j.ejca.2019.11.003
  30. Daly LE, Power DG, O’Reilly Á, Donnellan P, Cushen SJ, O’Sullivan K, Twomey M, Woodlock DP, Redmond HP, Ryan AM. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017;116(3):310-317.  https://doi.org/10.1038/bjc.2016.431
  31. Eun Y, Kim IY, Sun JM, Lee J, Cha HS, Koh EM, Kim H, Lee J. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019;9(1):14039. https://doi.org/10.1038/s41598-019-50574-6
  32. Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, Panting L, Jure-Kunkel M, Ji RR. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med. 2013;11:75.  https://doi.org/10.1186/1479-5876-11-75
  33. Khoja L, Atenafu EG, Templeton A, Qye Y, Chappell MA, Saibil S, Hogg D, Butler MO, Joshua AM. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med. 2016;5(10):2792-2799. https://doi.org/10.1002/cam4.878
  34. Nakamura Y, Tanaka R, Maruyama H, Ishitsuka Y, Okiyama N, Watanabe R, Fujimoto M, Fujisawa Y. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol. 2019;49(5):431-437.  https://doi.org/10.1093/jjco/hyy201
  35. Damuzzo V, Solito S, Pinton L, Carrozzo E, Valpione S, Pigozzo J, Arboretti Giancristofaro R, Chiarion-Sileni V, Mandruzzato S. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology. 2016;5(12):e1249559. https://doi.org/10.1080/2162402x.2016.1249559
  36. Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017;77(6):1322-1330. https://doi.org/10.1158/0008-5472.CAN-16-2324
  37. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368-1379. https://doi.org/10.1093/annonc/mdx363.021
  38. Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Investig. 2018;128(2):715-720.  https://doi.org/10.1172/jci96798
  39. Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 2017;19(10):848-855.  https://doi.org/10.1016/j.neo.2017.08.004
  40. Callahan MK, Yang A, Tandon S, Xu Y, Subudhi SK, Roman RA, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011;29(suppl):abstr 2505.
  41. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705. https://doi.org/10.1371/journal.pone.0087705
  42. Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.  https://doi.org/10.1186/s40425-015-0081-1

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.